Traditional treatments for chronic granulocytic leukemia include chemotherapy, interferon, and hematopoietic stem cell transplantation, but all have certain limitations and adverse effects. In recent years, molecular targeted therapy has achieved good results in clinical practice. Specific treatments are as follows: 1. Tyrosine kinase inhibitors (TKI): Targeted means that TKI can be accurately targeted to act on chronic granulocytic leukemia cells, while having less effect on normal cells, so the efficacy is better and the side effects are less. Tyrosine kinase inhibitor therapy should be preferred. 90% of patients currently treated with tyrosine kinase inhibitors can survive for a long time, and it is easy to take with fewer side effects; 2. Treatment with interferon: patients who cannot be treated with tyrosine kinase inhibitors can be considered for interferon-based treatment programs, or allogeneic hematopoietic stem cell transplantation; 3. Treatment with hydroxyurea: currently still The more commonly used hydroxyurea treatment, but its treatment can only control the blood picture and is not beneficial for the remission of the disease and long-term survival. The existing domestic tyrosine kinase inhibitors can reduce the economic pressure, and patients with chronic granulocytic leukemia should try to prefer TKI treatment; 4.